Sam S. Chang, MD, MBA

home / authors / sam-s-chang-md-mba

Articles

Dr. Chang on Efforts to Improve Quality of Life in Prostate Cancer

Dr. Chang on Efforts to Improve Quality of Life in Prostate Cancer

Sam S. Chang, MD, MBA
April 30th 2020

Sam S. Chang, MD, MBA, discusses the importance of quality of life in prostate cancer.

Read More

Dr. Chang on Questions Regarding Molecular Testing in Prostate Cancer

Dr. Chang on Questions Regarding Molecular Testing in Prostate Cancer

Sam S. Chang, MD, MBA
April 23rd 2020

Sam S. Chang, MD, MBA, discusses remaining questions regarding molecular testing in prostate cancer.

Read More

Dr. Chang on Adjuvant Versus Salvage Radiation in High-Risk Prostate Cancer

Dr. Chang on Adjuvant Versus Salvage Radiation in High-Risk Prostate Cancer

Sam S. Chang, MD, MBA
February 4th 2020

Sam S. Chang, MD, MBA, discusses adjuvant versus salvage radiation in patients with nonmetastatic high-risk prostate cancer.

Read More

Dr. Chang on the Evolution of Surgical Techniques in Prostate Cancer

Dr. Chang on the Evolution of Surgical Techniques in Prostate Cancer

Sam S. Chang, MD, MBA
January 9th 2020

Sam S. Chang, MD, MBA, discusses the evolution of surgical techniques in prostate cancer.

Read More

Dr. Chang on the Use of PARP Inhibitors in Prostate Cancer

Dr. Chang on the Use of PARP Inhibitors in Prostate Cancer

Sam S. Chang, MD, MBA
November 20th 2019

Sam S. Chang, MD, MBA, discusses the shift toward personalized therapy in prostate cancer.

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need